Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 744-749

  Abratt, R P ^a   Bezwoda, W R ^a   Goedhals, L ^a   Hacking, D J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0031032211     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.744     Document Type: Article

References (30)

1. Non Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 7:899-909, 1995
2. Cullen MH: The MIC regimen in non small cell lung cancer. Lung Cancer 9:S81-S89, 1993 (suppl 2)
3. Fernandez C, Rosell R, Abad-Esteve, et al.: Quality of life during chemotherapy in non small cell lung cancer patients. Acta Oncol 28:29-33, 1989
4. Heinemann V, Hertel LW, Grindey GB, et al.: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031, 1988
5. Plunkett W, Huang P, Xu YZ, et al.: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10, 1995
6. Abratt RP, Bezwoda WR, Falkson G, et al.: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
7. Anderson H, Lund B, Bach F, et al.: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer. A phase II study. J Clin Oncol 12:1821-1826, 1994
8. Fossella FV, Lippman SM, Shin DM, et al.: Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. 15:310-316, 1997
9. Gatzemeier U, Shepherd FA, Le Chevalier T, et al.: Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended phase II study. Eur J Cancer 32:243-248, 1996
10. Loehrer PJ, Einhorn LH: Cisplatin. Ann Intern Med 100:704-713, 1984
11. Peters GJ, Bergman AM, Ruiz van Haperen VWT, et al.: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79, 1995 (suppl 11)
12. Valeriote FA, Edelstein MB: The role of cell kinetics in cancer chemotherapy. Semin Oncol 4:217-226, 1977
13. Tonato M, Mosconi AM, Martin C: Safety profile of gemcitabine. Anticancer Drugs 6:27-32, 1995 (suppl 6)
14. Zamble DM, Lippard SJ: Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20:435-439, 1995
15. Crino L, Seagliotti G, Marangolo M, et al.: Gemcitabine-cisplatin combination in non-small cell lung cancer (NSCLC). A phase II study. Eur J Cancer 31A:S222, 1995 (suppl 5, abstr 1064)
16. Sandler A, Ansari R, McClean J, et al.: Gemcitabine plus cisplatin in non-small cell lung cancer: A phase II study. Eur J Cancer 131A:S225, 1995 (suppl 5, abstr 1079)
17. Steward WP, Dunlop DJ, Cameron C, et al.: Gemcitabine combined with cisplatin in non-small cell lung cancer (NSCLC): A phase I/II study. Eur J Cancer 31A:S225, 1995 (suppl 5, abstr 1081)
18. Anton A, Carrato A, Gonzalez Lariba JL: Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 15:380, 1996 (abstr 1134)
19. Shepherd F, Cormier Y, Burkes R: Phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematic modeling to determine the maximum-tolerable dose. J Clin Oncol 14:1656-1662, 1996
20. Cullen MH, Joshi R, Chetiyawardana AD, et al.: Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: Treatment good enough to compare. Br J Cancer 58:359-361, 1988
21. Weick JK, Crowley J, Natale RB, et al.: A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 9:1157-1162, 1991
22. Rosso R, Salvati F, Ardizzoni A, et al.: Etoposide versus etoposide plus high dose cisplatin in the management of advanced non-small cell lung cancer. Cancer 66:130-134, 1990
23. Crino L, Tonato M, Darvish S, et al.: A randomized trial of three cisplatin-containing regimens in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 26:52-56, 1990
24. Cartei G, Cartei F, Cantone A, et al.: Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for the treatment of non-small cell lung cancer. J Natl Cancer Inst 85:794-800, 1993
25. Rapp E, Pater JL, William A, et al.: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
26. Kaasa S, Lund E, Thorad E, et al.: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 67:2443-2447, 1991
27. Ganz PA, Figlin RA, Haskell CM: Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer 63:1271-1278, 1989
28. Woods RL, Williams CS, Page J, et al.: A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61:608-611, 1990
29. Quoix E, Dietmann A, Charbonneau J, et al.: Is cisplatin based chemotherapy useful in disseminated non-small cell lung cancer? Bull Cancer 78:341-346, 1991
30. Le Chevalier T, Brisgand D, Douillard JY, et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine in advanced non-small-cell lung cancer - Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994